| Company/Division name | Fresenius Kabi with Phlow |
| Parent company | Fresenius SE & Co. KGaA with Phlow |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2026 |
| Year reshoring implemented or to be implemented: | 2027 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | to state, add NY, NC, IL |
| Country(ies) from which reshored: | Germany |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | Epinephrin |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Infrastructure, Manufacturing/engineering joint innovation (R&D) |
